Isotechnika Completes Patient Recruitment of Pivotal Phase 3 Psoriasis Trial.

PR Newswire Europe, July, 2007

EDMONTON, Canada, July 23 /PRNewswire/ -- Isotechnika Inc. (TSX:ISA) announced today that the Company has completed recruitment of its pivotal Phase 3 European/Canadian psoriasis trial (ESSENCE). As of July 20, 2007, the Company closed recruitment at 638 patients. The patient population is made up of 228 Canadian patients, 294 patients from Germany and 116 patients from Poland. "We are pleased that patient recruitment was achieved in the anticipated timeframe," stated Dr. Randall Yatscoff, Isotechnika's President & CEO. "The ability to complete recruitment quickly speaks to the unmet medical need for a treatment for this serious and debilitating disease. This is a major milestone in facilitating the advancement of ISA247 towards final marketing approval for the...